# Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct02455141/  
OnCo record `nct02455141` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of epirubicin, cyclophosphamide and carboplatin in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, active but no longer recruiting.

## Summary

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer is a phase 3, randomised interventional study registered as NCT02455141 by Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 786 participants, started 2016-03 and due to reach its primary completion in 2027-03. Interventions recorded: Epirubicin plus Cyclophosphamide; Taxanes; Taxanes plus Carboplatin. Conditions listed: Breast Neoplasm. Triple-negative eligibility wording from the registry: "* Tumor specimens are available for estrogen receptor (ER), progesterone receptor (PgR) and Her2 (human epidermal-growth-factor receptor 2) detection, patients should be with triple negative breast cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: TCTN
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT02455141
- Phase: 3
- Setting: Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial
- Sponsor: Shanghai Jiao Tong University School of Medicine
- Enrolled: 786

## Sources

- ClinicalTrials.gov NCT02455141: https://clinicaltrials.gov/study/NCT02455141

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Epirubicin](https://onco.cc/drugs/epirubicin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct02455141.json